Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

@article{Kelly2001PaclitaxelEP,
  title={Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.},
  author={William Kevin Kelly and Tracy Curley and Susan R. Slovin and Glenn Heller and Judith McCaffrey and Dean E Bajorin and Allison L Ciolino and Kevin Regan and Michael C. Schwartz and Philip W. Kantoff and Daniel Houser George and William K Oh and Margaret Smith and Dixon Kaufman and Eric Jay Small and Lawrence Schwartz and Steven Larson and William Tong and Howard Scher},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 1},
  pages={44-53}
}
PURPOSE To determine the safety and activity of weekly paclitaxel in combination with estramustine and carboplatin (TEC) in patients with advanced prostate cancer. PATIENTS AND METHODS In a dose-escalation study, patients with advanced prostate cancer were administered paclitaxel (weekly 1-hour infusions of 60 to 100 mg/m(2)), oral estramustine (10 mg/kg), and carboplatin (area under the curve, 6 mg/mL-min every 4 weeks). Paclitaxel levels were determined 0, 30, 60, 90, and 120 minutes and 18… CONTINUE READING
49 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Similar Papers

Loading similar papers…